- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Tags
economic development Animal biotechnology BIO BIOTECH Intellectual Property economy vaccines patent United States Patent and Trademark Office biotech industry FDA NIH Patent Reform biotechnology USPTO innovation drug development Technology Transfer BIO International Convention 2012 BIO International ConventionAuthors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Category Archives: Public Policy
Latest From Public Policy
Australian Senate Committee Recommends Against Banning ‘Gene Patents’
The Australian Senate Legal and Constitutional Affairs Legislation Committee recommended against the Patent Amendment (Human Genes and Biological Materials) which would have banned DNA patents in Australia. The push by members of the Australian Senate seemed to mirror efforts in the United States surrounding the Myriad case. The Committee found that: “While previous inquiries and public discussions have focused on the patenting of human genes, the Bill goes further and proposes a specific exclusion for biological materials which Read More >
Biotechnology Industry Initiative to Improve U.S. Science Education
By Bianca Blanks, Biotechnology Institute Industry responds to President’s “Educate to Innovate” campaign with “Scientists in the Classroom” initiative The Biotechnology Institute supports STEM education and has a vision to capture the imagination of youth, to inspire the next generation to learn life science and biotechnology, and transform society’s expectations so that all citizens may appreciate the importance of biotechnology to society. The Biotechnology Institute’s Scientists in the Classroom initiative is the life science industry’s Read More >
Bi-partisan Senate Letter asking for 12 years of Data Protection in TPP
Senators Hatch and Kerry, along with 35 other Senators, sent a letter to Ambassador Kirk asking for 12 years of regulatory data protection consistent with U.S. law in the Trans Pacific Partnership Agreement. We are united in urging you to propose a strong minimum term of regulatory data protection for biologics consistent with U.S. law. As you are aware, U.S. law provides for a 12-year term of regulatory data protection for biologics and we believe that should serve Read More >
Data Protection, Trans Pacific Partnership, and the US-Jordan FTA (Post 2 of 2)
This post is a continuation of a previous post: Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2). 4. Oxfam criticizes pharmaceutical innovators for not making all of their innovative drugs available in Jordan. Ryan responds: a. Innovator companies introduced few new drugs before IP reform because local companies were using their know-how and clinical data to get marketing approval and brochures describing the drug’s therapeutic function and side effects Read More >
Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2)
The Trans Pacific Partnership (TPP) negotiation does not yet include a section on data protection (typically included in the Pharmaceutical Chapter of Free Trade Agreements). Organizations against the inclusion of data protection in the TPP cite as evidence an Oxfam International study titled “All Costs, No Benefits: How TRIPS-plus intellectual property rules in the US-Jordan FTA affect access to medicines.” The Oxfam paper concludes that “medicine prices have increased drastically, and TRIPS-plus rules were partly Read More >
